TEL AVIV, Israel, July 30, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), today announced that the company will host an ADHD seminar on Tuesday, August 6, 2013 from 12:00pm to 2:00pm Eastern Time (7:00 p.m. Israeli Time) in New York City.
Keynote speaker, Dr. Lenard A. Adler, will join Alcobra's management team for the presentations. Dr. Adler is the Professor of Psychiatry and Child and Adolescent Psychiatry at New York University School of Medicine. He is also the Chairman of the Clinical Advisory Board for Alcobra.
This event will be available via webcast and can be accessed through the Alcobra website, http://www.alcobra-pharma.com/events.cfm. Please allow extra time prior to the event to visit the site and download any necessary software to listen to the live broadcast. An archive of the event will be available for 90 days.
Analysts and investors who would like to register or learn more about the event should contact Diane Imas or Alex Woodbury of KCSA Strategic Communications at (212) 896-1267 or firstname.lastname@example.org. Registration is required as space is limited.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.
Forward Looking Statements
This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties, including, among others, risks that could cause results to differ materially from those expected by the management of Alcobra Ltd. More detailed information about the risks and uncertainties affecting Alcobra Ltd.is contained under the heading "Risk Factors" in Alcobra Ltd.'s registration statement on Form F-1 filed with the SEC, which is available on the SEC's web site, www.sec.gov. Alcobra Ltd. undertakes no obligation to update or revise any forward-looking statements.
CONTACT: U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 212.896.1249 / +1 212.896.1250 email@example.com / firstname.lastname@example.org Israel Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620 email@example.comSource:Alcobra Ltd.